Mangoceuticals Inc Dossier - Source-backed chat

Mangoceuticals Inc

MGRXNASDAQ

SectorHealth Care

IndustryHealth Care Technology

Beta (adjusted)1.64

Intrinsic Value

No headline value published yetWe haven't published a headline intrinsic value for this company yet. Our data-reliability standards weren't met. Method estimates are shown for reference.

Market Price $0.48Price as of 1 Oct 2026

Data confidence Sign in to view data confidence

Market Cap $10.4M

Enterprise Value $10.4M

Shares Outstanding 19.6M diluted

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Mangoceuticals, Inc. (MGRX) is a micro-cap telemedicine company facing severe financial distress, characterized by rapidly declining revenues, substantial net losses, and an extremely thin cash runway. The company's core business model relies heavily on high-cost digital marketing and customer acquisition, which has resulted in unsustainable cash burn. Furthermore, the company faces significant regulatory and compliance risks, including Nasdaq non-compliance due to its low share price, and operational instability highlighted by delayed SEC filings. Given these compounding risks and the lack of a clear path to profitability, the stock presents a highly unfavorable risk-reward profile for investors.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

In the bear case, Mangoceuticals is unable to secure additional financing on acceptable terms, leading to a severe liquidity crisis. The company's cash reserves, which stood at just $174,562 as of March 31, 2026, are completely depleted, forcing a halt to operations or restructuring. Additionally, the company fails to regain compliance with Nasdaq's minimum bid price requirement, resulting in the delisting of its common stock to over-the-counter (OTC) markets, which would severely restrict liquidity and wipe out remaining equity value.

Base CaseCentral scenario

The base case assumes that Mangoceuticals continues to struggle with low revenue generation and high operational expenses. While the company may succeed in raising short-term capital through highly dilutive equity offerings or private placements, these measures will only temporarily extend its runway without addressing the fundamental unprofitability of its business model. Revenue is expected to remain minimal as the company attempts to rebuild its platform and launch new product lines, while net losses will continue to accumulate, leading to further shareholder dilution and downward pressure on the stock price.

Scenarios reflect our research view at the research date.

Key Investment Merits

Expansion of product offerings into high-growth areas such as Testosterone Replacement Therapy (TRT) and weight management.
Active pursuit of intellectual property and patent filings, such as the MGX-0024 antiviral technology.
Potential recovery of damages from the $73 million lawsuit against former technology consultant Clarity Ventures, Inc.

Key Investment Risks

Severe liquidity risk with cash on hand of only $174,562 against a quarterly net loss of $3.4 million as of March 31, 2026.
High risk of ongoing equity dilution due to the frequent need for dilutive financing transactions to fund operations.
Regulatory and listing risks, including the threat of delisting from the Nasdaq Capital Market due to non-compliance with the minimum bid price rule.

Thesis Invalidation Triggers

Securing a major, non-dilutive strategic partnership or licensing agreement that provides substantial upfront capital.
A highly favorable and rapid settlement or judgment in the lawsuit against Clarity Ventures, Inc., resulting in a significant cash influx.
An unexpected and dramatic acceleration in revenue growth and customer acquisition that significantly reduces the cash burn rate.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.